Already have an account?


Login with an existing Projects In Knowledge account Log in with your MPT account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD
  • Breast Cancer — Case Study: CDK4/6 Inhibition in the Management of a Premenopausal Woman With Advanced/Metastatic HR-Positive Breast Cancer – @Point of Care Chapter
  • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most common subtype of breast cancer. Endocrine therapy is standard for this subtype. Although HR-positive, HER2-negative breast cancer has the best prognosis overall among clinical breast cancer ... more >>
    L. Spring, MD
  • Ovarian Cancer — Case Study: Late-Line Treatment of a Patient With Recurrent Ovarian Cancer – @Point of Care Chapter
  • Patients with late-line, recurrent ovarian cancer are eligible for treatment with a single-agent poly (ADP-ribose) polymerase (PARP) inhibitor. At this stage of disease, treatment decisions must take into account previous lines of treatment, patient preference, tumor mutational status, efficacy, and potential ... more >>
    B. Monk, MD, FACS, FACOG
  • Multiple Sclerosis — ECTRIMS: Siponimod Reduces Loss of Gray Matter in Secondary Progressive Multiple Sclerosis – BreakingMED
  • There is increasing attention being paid to cortical gray matter loss and its effect on patients with secondary progressive MS. This report, which is based on findings reported at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden, September 11-13, 2019, ... more >>
    K. Rodowicz, DO
  • Heart Failure — HFSA: Dapagliflozin Misses Mark for HF Biomarker, But Improves Function – BreakingMED
  • The diabetes drug dapagliflozin may also have a role in reduced ejection fraction heart failure; however, DEFINE-HF results reported at the Heart Failure Society of America meeting in Philadelphia, September 13-16, 2019 delivered mixed findings.
    V. Abramson, MD
  • Renal Cell Carcinoma — Renal Cell Carcinoma: Novel and Evolving Immunotherapeutic Approaches – @Point of Care Chapter
  • Approved and emerging immunotherapies hold promise for the treatment of patients with renal cell carcinoma (RCC). As the results of ongoing studies have been favorable, standard treatment now includes immunotherapeutics. In this activity, Robert J. Motzer, MD, reviews what is known about the safety and ... more >>
    J. Weber, MD, PhD
  • Heart Failure — HFSA: The Findings Are Positive, But Sacubitril/Valsartan Rx Lags – BreakingMED
  • Trial results, like some other things, can be better appreciated the second time around, which appeared to be the case when investigators for PARAGON-HF and PROVE-HF stepped on stage for encore presentations of their results at the Heart Failure Society of America 2019 meeting in Philadelphia, September 13-16 ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — ECTRIMS: Leukemia Drug Ofatumumab Shows Superior Efficacy to Teriflunomide in MS – BreakingMED
  • Managing relapsing MS can be clinically challenging. This report, which is based on findings reported at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden, September 11-13, 2019, discusses two phase III trials of ofatumumab, a leukemia drug not yet approved ... more >>
    K. Rodowicz, DO
  • Asthma — Case Study: Management of a Patient With Eosinophilic Asthma – @Point of Care Chapter
  • Several biologics are now available to treat severe asthma with a type 2-high endotype. These include monoclonal antibodies targeting immunoglobulin E (IgE), interleukin (IL)-5, and IL-4/IL-13. Biomarkers may help predict response to these therapeutics; however this is still an evolving area, making choice of ... more >>
    P. Akuthota, MD
  • Heart Failure — HFSA: Heart Failure Research in the U.S. Is Sub-Optimal – BreakingMED
  • Clinical trials in heart failure treatment are vital for increasing awareness and treatment options; however, U.S. research into HF and other diseases has seen a sharp decline in recent years. This report from the Heart Failure Society of America meeting in Philadelphia, September 13-16, takes a look at the " ... more >>
    V. Abramson, MD
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Master Class: Chronic Lymphocytic Leukemia
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... more >>
    B. Cheson, MD, FACP, FAAAS
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Mastery of Medicine in Diabetes Management
  • Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... more >>
    V. Fonseca, MD, FRCP
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Rheumatology Mastery in Rheumatoid Arthritis
  • Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... more >>
    M. Husni, MD, MPH
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Rheumatology Mastery In Ankylosing Spondylitis
  • Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... more >>
    J. Reveille, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Heart Failure — HFSA: The Findings Are Positive, But Sacubitril/Valsartan Rx Lags – BreakingMED
  • Trial results, like some other things, can be better appreciated the second time around, which appeared to be the case when investigators for PARAGON-HF and PROVE-HF stepped on stage for encore presentations of their results at the Heart Failure Society of America 2019 meeting in Philadelphia, September 13-16 ... more >>
    V. Abramson, MD
  • Heart Failure — HFSA: Dapagliflozin Misses Mark for HF Biomarker, But Improves Function – BreakingMED
  • The diabetes drug dapagliflozin may also have a role in reduced ejection fraction heart failure; however, DEFINE-HF results reported at the Heart Failure Society of America meeting in Philadelphia, September 13-16, 2019 delivered mixed findings.
    V. Abramson, MD
  • Heart Failure — HFSA: Heart Failure Research in the U.S. Is Sub-Optimal – BreakingMED
  • Clinical trials in heart failure treatment are vital for increasing awareness and treatment options; however, U.S. research into HF and other diseases has seen a sharp decline in recent years. This report from the Heart Failure Society of America meeting in Philadelphia, September 13-16, takes a look at the " ... more >>
    V. Abramson, MD
  • Heart Failure — HFSA: Sacubitril/Valsartan Demonstrates Benefit in Hospitalized Black HFrEF Patients – BreakingMED
  • Is treatment with sacubitril/valsartan beneficial for black patients hospitalized with acute decompensated reduced ejection fraction heart failure? A post-hoc analysis of PIONEER-HF found significant improvement in a key biomarker, as well as significant clinical benefit, according to this report from the ... more >>
    V. Abramson, MD
  • Heart Failure — HFSA: Hospitalized HF Patients Addressed in ACC Consensus Decision Pathway – BreakingMED
  • Integrating GDMT into daily management of patients with reduced ejection fraction heart failure (HFrEF) has dramatically improved patient outcomes in recent years. This report describes the 2019 ACC expect decision pathway for hospitalized HF patients, which was released as the Heart Failure Society of ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — Ponesimod Bests Teriflunomide in Head-to-Head MS Trial – BreakingMED
  • Understanding current available therapies for management of relapsing multiple sclerosis is challenging and likely to become increasingly so as new agents are approved. This report, which is based on findings reported at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in ... more >>
    V. Abramson, MD
  • Heart Failure — ESC: Unwinding the Mechanism of Clinically Beneficial HF Therapies – BreakingMED
  • Heart failure took and held the spotlight at the ESC 2019 with a series of Hot Line presentations that may have an immediate influence on clinical decisions. This report reviews results of two ARNI studies: PROVE-HF and EVALUATE-HF, as well as an analysis of temporal trends in HFrEF mortality.
    V. Abramson, MD
  • Heart Failure — ESC: Diabetes Drug Provides Significant Benefit in Heart Failure – BreakingMED
  • Improving outcomes in patients with reduced ejection fraction heart failure (HFrEF) remains challenging, even in the era of ARNI, but research reported at the European Society of Cardiology suggests that a diabetes drug -- dapagliflozin -- may be a game changer.
    K. Rodowicz, DO
  • Heart Failure — ESC: Prevention of Acute Heart Failure Should Be Treatment Goal – BreakingMED
  • Almost half of the 2 million acute heart failure patients hospitalized annually in the U.S. and Europe will die or be re-hospitalized within 6 months. This report based on research reported at the European Society of Cardiology meeting in Paris suggests that improving that grim prognosis will require some ... more >>
    A. Brixey, MD
  • Heart Failure — ESC: Swede HF Underlines Life-Saving Potential of ICDs – BreakingMED
  • More than 17 years have passed since researchers first reported the success of prophylactic ICD use to reduce mortality in persons with reduced ejection fraction heart failure following myocardial infarction, and in 2019 ICDs are still saving lives, as researchers reported at the European Society of ... more >>
    A. Brixey, MD
  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD
  • Multiple Sclerosis — RRMS Patient with Active On-Treatment Disease Considering a Switch to a Selective Oral S1P Inhibitor – Case Study
  • In this case, the diagnosis and initial treatment of a patient with relapsing multiple sclerosis (MS) is reviewed. This illustrates the considerations that occur when a patient has a clinical relapse while on disease-modifying therapy and highlights available and emerging oral therapies for the treatment of ... more >>
    C. Azevedo, MD, MPH
  • Multiple Sclerosis — Case Study: Misdiagnosis in MS – Case Study
  • The 2017 revisions to the McDonald criteria have refined the diagnosis of multiple sclerosis (MS). However, these criteria must only be applied to patients with symptoms typical of demyelination. In addition, there must be "no better explanation." This case follows the skillful navigation of diagnosis in a 56 ... more >>
    A. Solomon, MD
  • Multiple Sclerosis — Risk-Averse RRMS Patient With a Preference for an Oral DMT – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) who has a clinical relapse on his first disease-modifying therapy. It illustrates considerations when switching medications, including patient preference for therapeutic delivery, and ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — Case Study: Patient With Secondary-Progressive MS and Active Disease – Case Study
  • This case study follows a 39-year-old man who developed relapsing-remitting multiple sclerosis (MS) when he was 34. He is being treated with an oral agent for relapsing MS; however he has since advanced to secondary-progressive MS (SPMS) and shows signs of active disease radiographically. New treatment ... more >>
    E. Williamson, MD
  • Multiple Sclerosis — Patient with Active Relapsing MS at High Risk for PML – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) that is following an aggressive clinical course. It illustrates the considerations that should occur when initiating and switching disease modifying therapies (DMTs), as well as highlighting ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — An African American Patient with Increasing Symptoms: Managing a Newly Diagnosed Patient with PPMS – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with primary progressive multiple sclerosis (PPMS). It illustrates the considerations involved in selection of treatment for patients with progressive forms of MS, as well as highlighting the natural course of progressive disease and the ... more >>
    J. Rinker, MD
  • Multiple Sclerosis — A Patient with RRMS Who Experiences Breakthrough Disease on Two Disease-Modifying Therapies – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing-remitting multiple sclerosis (RRMS) who has breakthrough disease activity on her first disease-modifying therapy (DMT) and switches to a different class of DMT. After doing well on her second DMT for awhile, she experiences ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — RRMS Patient With Newly Diagnosed SPMS After Experiencing Increased Disability and Disease Progression – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing multiple sclerosis (MS) who has been treated with two disease modifying treatments (DMTs) and now presents with symptoms of secondary progressive MS (SPMS). The activity highlights how environmental factors and comorbidities ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — An RRMS Patient With Disease Breakthrough and the Need to Switch Therapy – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing-remitting multiple sclerosis (MS) who is on her first disease-modifying therapy (DMT) but has breakthrough disease. It highlights considerations for switching DMTs in a patient with mild to moderate MS disease activity, ... more >>
    J. Rinker, MD